BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

Bristol Myers (BMY) shares have dropped 16.3% year-to-date in 2025, significantly underperforming peers, primarily driven by intensifying generic competition for top-selling legacy drugs like Revlimid and Eliquis, alongside recent pipeline setbacks for candidates such as Camzyos and Cobenfy. While the company reported a strong Q1 and is diversifying its portfolio with newer drugs like Reblozyl, Breyanzi, and Opdualag, these efforts are challenged by the headwinds and a substantial $46.1 billion long-term debt. Consequently, investor sentiment remains cautious, with new drugs expected to take time to fully offset declines, leading to a mixed outlook where prospective investors are advised to 'wait and watch,' while existing holders may find reason to stay invested due to the attractive 5.35% dividend yield.

Analysis

Bristol Myers (BMY) is navigating a challenging transition period, marked by a 16.3% year-to-date share price decline in 2025, significantly underperforming its industry and the broader market. This negative performance is primarily driven by two factors: intensifying generic competition eroding revenues from legacy drugs like Revlimid and Pomalyst, and recent pipeline setbacks that have dampened investor sentiment. Specifically, the failure of the Camzyos ODYSSEY-HCM study and the Cobenfy ARISE study to meet their primary endpoints raises questions about near-term growth catalysts. Furthermore, the company's balance sheet carries a substantial long-term debt of $46.1 billion. In response, BMY is relying on its portfolio of newer drugs—including Reblozyl, Breyanzi, and Opdualag—to stabilize its revenue base. The immuno-oncology franchise, led by Opdivo, continues to show solid growth, bolstered by recent European approvals for a subcutaneous formulation and expanded indications. Despite these positive developments and a low forward P/E valuation of 7.24x, downward revisions to 2025 and 2026 EPS estimates reflect persistent uncertainty about the pace at which new products can offset the decline of established blockbusters.

Key Decisions for Investors

• Prospective investors should consider a cautious stance, as significant headwinds from generic erosion and recent clinical trial failures may continue to pressure the stock in the near term, despite its discounted valuation.
• For existing shareholders, holding the position could be a prudent strategy, primarily supported by the stock's attractive 5.35% dividend yield which provides a cash return during this transitional phase.
• Investors should closely monitor the commercial uptake and sales growth of the newer drug portfolio, particularly Reblozyl, Breyanzi, and Opdualag, as their performance is critical to offsetting the revenue decline from legacy assets.
• The high debt level of $46.1 billion is a key risk factor; therefore, monitoring the company's deleveraging progress and cash flow generation is essential for assessing long-term financial stability.